RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Retinopathy of Prematurity: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
The Relationship of Common Biomarkers with the Risk of Development and Progression of Retinopathy of Prematurity
Jannatul Naim et al., Journal of National Institute of Ophthalmology (15 October 2026)
https://doi.org/10.3329/jnio.v8i1.94290
- 2.
Telemedicine in Retinopathy of Prematurity: A Review of Current Evidence and Clinical Outcomes
Ilinca-Medeea Iftime et al., Children (15 October 2026)
https://doi.org/10.3390/children13101413
- 3.
Context-aware asymmetric ensembling for interpretable retinopathy of prematurity screening via active query and vascular attention.
Hassan Md Mehedi et al., Computers in biology and medicine (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42815088/
- 4.
Facilitators and Barriers to Retinopathy of Prematurity Screening in a Tertiary Care Facility: A Mixed-Methods Study
Michael Abel Alao et al., Research Square (14 October 2026)
https://doi.org/10.21203/rs.3.rs-10765471/v1
- 5.
Late-onset sequelae of untreated, spontaneously regressed retinopathy of prematurity presenting as retinal breaks.
Bavaskar Snehal et al., BMJ case reports (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42869561/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263 · Active (not recruiting) · Phase 2 · OHB Neonatology Ltd.
Ages 0 Hours to 24 Hours
https://clinicaltrials.gov/study/NCT03253263
- 2.
Acupuncture for Preterm Infants Requiring Eye-exam
NCT03650621 · Completed · University of Alberta
Ages 29 Weeks to 36 Weeks
https://clinicaltrials.gov/study/NCT03650621
- 3.
Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis
NCT01124331 · Completed · University of Sydney
Up to age 24 Hours
https://clinicaltrials.gov/study/NCT01124331
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Retinopathy of Prematurity
Retinopathy of prematurity is an eye condition that affects babies born very early, in which the blood vessels of the retina grow abnormally. Mild cases often settle on their own, but severe disease can scar the retina or pull it out of place and threaten sight. Babies at risk are screened regularly, and treatment may involve laser therapy or injections of anti-VEGF medicine.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Background: Retinopathy of prematurity (ROP) is a potentially blinding vasoproliferative retinal disorder affecting preterm infants. Although prematurity and low birth weight are established risk factors, increasing evidence suggests that hematological biomarkers may influence the development and progression of ROP. Data from Bangladesh regarding this association are scarce. Objective: To evaluate the relationship of common blood biomarkers—hemoglobin (Hb), platelet count, lymphocyte count, neutrophil count, and HbA1c—with the risk of development and progression of ROP. Methods: This prospective observational study was conducted at the National Institute of Ophthalmology & Hospital, Dhaka, from July 2022 to June 2023. Preterm infants meeting ROP screening criteria were enrolled. Ophthalmoscopic examinations were performed at the first visit (4th postnatal week) and during follow-up until 42 weeks postmenstrual age. Blood biomarkers were measured at the 4th week of life. Associations between biomarkers and ROP development and progression were analyzed using independent sample t-tests. Results: Of the 59 infants analyzed, 22 (37.3%) developed ROP. Infants with ROP had significantly lower hemoglobin levels (10.7 ± 2.3 vs 12.1 ± 1.9 g/dL; p = 0.016) and higher lymphocyte counts (4260.6 ± 1789.9 vs 3388.2 ± 1161.7 cells/cmm; p = 0.027) compared to non-ROP infants. No significant association was found between ROP development and platelet count, neutrophil count, or HbA1c. Among infants with ROP, disease progression occurred in 50%, but none of the biomarkers showed a significant association with progression (p > 0.05). Conclusion: Low hemoglobin levels and elevated lymphocyte counts are significantly associated with the development of ROP. These readily available biomarkers may help identify preterm infants at higher risk of ROP in resource-limited settings. J.Natl.Inst.Ophthalmol.2025;8(1): 32-35
Common Questions
What is Retinopathy of Prematurity?
Retinopathy of prematurity is an eye condition that affects babies born very early, in which the blood vessels of the retina grow abnormally. Mild cases often settle on their own, but severe disease can scar the retina or pull it out of place and threaten sight. Babies at risk are screened regularly, and treatment may involve laser therapy or injections of anti-VEGF medicine.
How many clinical trials are available for Retinopathy of Prematurity?
RareWays currently indexes 112 clinical trials for Retinopathy of Prematurity, of which 9 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Retinopathy of Prematurity come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Retinopathy of Prematurity.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.